| Literature DB >> 29944674 |
Jefferson A Rocha1,2,3, Nayra C S Rego1,3, Bruna T S Carvalho3, Francisco I Silva3, Jose A Sousa3, Ricardo M Ramos4, Ionara N G Passos2, Josué de Moraes5, Jose R S A Leite6, Francisco C A Lima1,3.
Abstract
Schistosomiasis affects million people and its control is widely dependent on a single drug, praziquantel. Computational chemistry has led to the development of new tools that predict molecular properties related to pharmacological potential. We conducted a theoretical study of the imizadole alkaloids of Pilocarpus microphyllus (Rutaceae) with schistosomicidal properties. The molecules of epiisopiloturine, epiisopilosine, isopilosine, pilosine, and macaubine were evaluated using theory models (B3lyp/SDD, B3lyp/6-31+G(d,p), B3lyp/6-311++G(d,p)). Absorption, distribution, metabolization, excretion, and toxicity (ADMET) predictions were used to determine the pharmacokinetic and pharmacodynamic properties of the alkaloids. After optimization, the molecules were submitted to molecular docking calculations with the purine nucleoside phosphorylase, thioredoxin glutathione reductase, methylthioadenosine phosphorylase, arginase, uridine phosphorylase, Cathepsin B1 and histone deacetylase 8 enzymes, which are possible targets of Schistosoma mansoni. The results showed that B3lyp/6-311++G(d,p) was the optimal model to describe the properties studied. Thermodynamic analysis showed that epiisopiloturine and epiisopilosine were the most stable isomers; however, the epiisopilosine ligand achieved a superior interaction with the enzymes studied in the molecular docking experiments, which corroborated the results of previous experimental studies on schistosomiasis.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29944674 PMCID: PMC6019389 DOI: 10.1371/journal.pone.0198476
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Optimized chemical structures of alkaloids.
a) epiisopiloturine, b) epiisopilosine, c) isopilosine, d) pilosine, and e) macaubine.
Atomic charges (in atomic unit, a.u.) by the Mulliken, Chelpg, and NBO methods of the epiisopiloturine, epiisopilosine, isopilosine, pilosine and macaubine alkaloids using the theoretical model B3lyp/6-311++G(d,p).
| EPI | EPIIS | ISOP | PILO | MAC | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chelp | NBO | Mull | Chelp | NBO | Mull | Chelp | NBO | Mull | Chelp | NBO | Mull | Chelp | NBO | Mull | |
| 0.105 | -0.406 | 0.017 | 0.063 | -0.415 | 0.005 | 0.115 | -0.415 | 0.014 | 0.113 | -0.417 | 0.005 | 0.098 | -0.414 | -0.003 | |
| -0.577 | -0.513 | 0.096 | -0.562 | -0.492 | -0.104 | -0.572 | -0.493 | -0.099 | -0.592 | -0.492 | -0.110 | -0.543 | -0.490 | -0.107 | |
| -0.456 | -0.547 | -0.009 | -0.429 | -0.544 | -0.016 | -0.414 | -0.543 | -0.023 | -0.441 | -0.547 | -0.025 | -0.452 | -0.543 | -0.088 | |
| -0.572 | -0.576 | -0.256 | -0.526 | -0.564 | -0.291 | -0.522 | -0.565 | -0.284 | -0.545 | -0.566 | -0.275 | -0.548 | -0.570 | -0.307 | |
| -0.564 | -0.746 | -0.207 | -0.593 | -0.741 | -0.210 | -0.541 | -0.751 | -0.142 | -0.568 | -0.735 | -0.177 | - | - | - | |
| 0.115 | 0.218 | 0.259 | 0.188 | 0.211 | 0.081 | 0.197 | 0.208 | 0.113 | 0.190 | 0.208 | 0.077 | 0.174 | 0.214 | 0.085 | |
| -0.163 | -0.347 | -0.316 | -0.276 | -0.352 | -0.303 | -0.371 | -0.352 | -0.325 | -0.370 | -0.350 | -0.293 | -0.277 | -0.353 | -0.389 | |
| 0.439 | 0.108 | 0.175 | -0.062 | 0.109 | 0.467 | -0.153 | 0.112 | 0.592 | -0.182 | 0.114 | 0.178 | -0.130 | 0.109 | 0.481 | |
| -0.377 | -0.401 | -0.984 | -0.234 | -0.410 | -0.694 | -0.056 | -0.417 | -0.792 | -0.010 | -0.428 | -0.341 | 0.068 | -0.447 | -1.043 | |
| 0.223 | -0.242 | 0.079 | 0.237 | -0.240 | 0.005 | 0.187 | -0.231 | -0.095 | 0.099 | -0.223 | 0.164 | 0.015 | 0.024 | 0.607 | |
| 0.695 | 0.817 | -0.221 | 0.639 | 0.828 | -0.060 | 0.614 | 0.818 | -0.206 | 0.667 | 0.822 | -0.002 | 0.741 | 0.775 | -0.071 | |
| 0.114 | -0.319 | -0.182 | 0.123 | -0.318 | 0.082 | 0.067 | -0.318 | 0.285 | 0.221 | -0.325 | -0.463 | -0.169 | -0.129 | 0.335 | |
| 0.145 | 0.139 | 0.298 | 0.108 | 0.132 | 0.152 | -0.073 | 0.133 | -0.284 | -0.014 | 0.130 | 0.183 | -0.102 | -0.600 | -0.545 | |
| 0.091 | -0.075 | 0.767 | 0.104 | -0.075 | 0.515 | 0.192 | -0.075 | 1.016 | 0.156 | -0.077 | 0.706 | - | - | - | |
| -0.177 | -0.199 | -0.319 | -0.163 | -0.202 | -0.034 | -0.158 | -0.201 | -0.231 | -0.161 | -0.202 | -0.110 | - | - | - | |
| -0.051 | -0.200 | -0.311 | -0.058 | -0.200 | -0.432 | -0.076 | -0.198 | -0.511 | -0.083 | -0.200 | -0.451 | - | - | - | |
| -0.118 | -0.200 | -0.446 | -0.114 | -0.199 | -0.339 | -0.106 | -0.196 | -0.382 | -0.100 | -0.199 | -0.351 | - | - | - | |
Distances of the atomic bonds (Å), atomic angles, and dihedral angles (°) of the alkaloids epiisopiloturine, epiisopilosine, isopilosine, pilosine and macaubine using the theoretical model B3lyp/6-311++G(d,p).
| B3lyp/6-311++G(d,p) | EPI | EPIIS | ISOP | PILO | MAC |
|---|---|---|---|---|---|
| N1 –C2 | 1.454 | 1.454 | 1.455 | 1.453 | 1.455 |
| N2 –C1 | 1.317 | 1.311 | 1.312 | 1.311 | 1.312 |
| O2 = C6 | 1.207 | 1.196 | 1.198 | 1.197 | 1.201 |
| O1 –C6 | 1.356 | 1.360 | 1.356 | 1.360 | 1.371 |
| O3 –C8 | 1.432 | 1.429 | 1.440 | 1.427 | - |
| N1 –C1 –N2 | 112.3 | 112.3 | 112.3 | 112.3 | 112.3 |
| C1 –N1 –C2 | 126.9 | 125.7 | 125.8 | 125.7 | 126.0 |
| C3 –C4 –C5 | 113.3 | 114.5 | 114.3 | 113.7 | 114.3 |
| O2 = C6—O1 | 122.2 | 121.9 | 122.1 | 121.9 | 122.7 |
| O3 –C8 –C7 | 106.3 | 106.5 | 106.3 | 108.0 | - |
| C7 –C8 –C9 | 115.1 | 115.4 | 114.1 | 114.3 | - |
| C8 –C9 –C10 | 119.2 | 119.0 | 120.4 | 119.1 | - |
| C4 –C5 –C7 –C8 | 140.7 | 82.4 | 88.2 | 41.2 | - |
| C5 –C7 –C8 –O3 | 63.3 | 62.2 | −45.0 | −75.1 | - |
Fig 2Relative energies in (kcal mol-1) of alkaloids isomers of EPI by theoretical models B3lyp/SDD (I), B3lyp/6-31+G(d,p) (II), and B3lyp/6-311++G(d,p) (III).
a) epiisopiloturine, b) epiisopilosine, c) isopilosine and d) pilosine.
Fig 3Graphic of the molecular orbitals HOMO and LUMO of the epiisopiloturine, epiisopilosine, isopilosine, pilosine and macaubine alkaloids using the theoretical model B3lyp/6-311++G(d,p).
Main assignments of the bands of the electronic spectrum of UV-Vis, energy, and types, calculated using the Swizard program for the molecular forms epiisopiloturine, epiisopilosine, isopilosine, pilosine and macaubine.
I = imidazole, D = dihydrofuran, B = benzene.
| Wavelength (nm) / Strength of the oscillator [f] | Composition | Energy (eV) | Type of charge transfer |
|---|---|---|---|
| EPI | |||
| 238 [0.0084] | 75→79 (28%) | 5.20 | CT BD-I |
| 237 [0.0021] | 76→78 (95%) | 5.23 | CT I-B |
| 230 [0.0229] | 73→77 (18%) | 5.38 | CT BD-BD |
| EPIIS | |||
| 244 [0.0057] | 76→78 (91%) | 5.08 | CT I-B |
| 238 [0.0008] | 76→77 (57%) | 5.20 | CT I-B |
| 237 [0.0150] | 75→77 (37%) | 5.23 | CT BD-B |
| ISOP | |||
| 249 [0.0203] | 76→77 (91%) | 4.96 | CT I-B |
| 243 [0.0002] | 76→79 (62%) | 5.10 | CT I-I |
| 237 [0.0042] | 74→77 (37%) | 5.23 | CT I-B |
| PILO | |||
| 253 [0.0026] | 76→77 (49%) | 4.89 | CT I-B |
| 243 [0.0034] | 76→78 (49%) | 5.09 | CT I-B |
| 236 [0.0034] | 76→79 (24%) | 5.23 | CT I-I |
| MAC | |||
| 281 [0.0139] | 51→52 (98%) | 4.40 | CT I-D |
| 253 [0.0004] | 49→52 (38%) | 4.90 | CT I-D |
| 237 [0.0010] | 51→53 (97%) | 5.23 | CT I-I |
Fig 4The molecular orbitals HOMO and LUMO of the epiisopiloturine, epiisopilosine, isopilosine, pilosine and macaubine alkaloids calculated using the theoretical model B3lyp/6-311++G(d,p) in the Swizard program.
Fig 5UV-Vis spectrum of the epiisopiloturine, epiisopilosine, isopilosine, pilosine and macaubine alkaloids using the theoretical model B3lyp/6-311++G(d,p).
Fig 6Electronic density of alkaloids.
a) epiisopiloturine, b) epiisopilosine, c) isopilosine, d) pilosine, and e) macaubine, using the theoretical model B3lyp/6-311++G(d,p). The colors represent red (negative) and blue (positive).
ADMET predictions of the epiisopiloturine, epiisopilosine, isopilosine, pilosine and macaubine alkaloids.
| ADMET | EPI | EPIIS/ISOP/PILO | MAC |
|---|---|---|---|
| Plasma protein binding (PPB) (%) | 63.140757 | 63.940875 | 37.146972 |
| Blood-brain barrier penetration (BBB) (C, brain/C, blood) | 0.011675 | 0.0167958 | 0.992212 |
| Skin Permeability (logKp, cm/h) | -3.86369 | -3.89764 | -3.0451 |
| Human intestinal absorption (HIA, %) | 96.050121 | 96.050121 | 97.523105 |
| Caco-2 cell Permeability (nm/s) | 21.8393 | 22.8681 | 27.2895 |
| MDCK cell permeability (nm/s) | 16.0498 | 9.63097 | 15.7929 |
| P-glycoprotein inhibition | Non | Non | Non |
| Water solubility in buffer (mg/L) | 23332.8 | 78158.6 | 3810.15 |
| Pure water solubility (mg/L) | 8525.04 | 21880 | 110732 |
| Ames test | Mutagen | Mutagen | Mutagen |
| Ames TA100 (+S9) | Negative | Negative | Positive |
| Ames TA100 (-S9) | Negative | Negative | Positive |
| Ames TA1535 (+S9) | Negative | Negative | Positive |
| Ames TA1535 (-S9) | Negative | Negative | Positive |
| Carcinogenicity (Mouse) | Negative | Negative | Negative |
| Carcinogenicity (Rat) | Negative | Negative | Negative |
| CYP 2C19 inhibition | Inhibitor | Inhibitor | Inhibitor |
| CYP 2C9 inhibition | Inhibitor | Inhibitor | Inhibitor |
| CYP 2D6 inhibition | Non | Non | Non |
| CYP 2D6 substrate | Non | Non | Weakly |
| CYP 3A4 inhibition | Inhibitor | Inhibitor | Inhibitor |
| CYP 3A4 substrate | Substrate | Substrate | Substrate |
| Lipinski’s Rule | Suitable | Suitable | Suitable |
| WDI-like Rule | Within 90% cutoff | Within 90% cutoff | Within 90% cutoff |
| Lead-like Rule | Binding affinity > 0.1 μM | Binding affinity > 0.1 μM | Violated |
| CMC-like Rule | Qualified | Qualified | Qualified |
| MDDR-like Rule | Mid-structure | Mid-structure | Mid-structure |
Molecular affinity parameters of the epiisopiloturine, epiisopilosine, isopilosine, pilosine and macaubine alkaloids with S. mansoni enzymes by the autodock program.
| Complex | ΔGbind
| Ki | Number of independent docking runs | Number of conformations in the first ranked cluster | Amino acids that interact through hydrogen bonds | Amino acids that make hydrophobic interactions |
|---|---|---|---|---|---|---|
| Up/epiis | -7.68 | 2.36 μM | 100 | 73 | Arg203(2), Gln201, Met231 | Arg121, Gly126, Glu234, Glu232, Ile265, Met233, Phe197, Phe272, Ser125, Thr124-10 |
| Tgr/epiis | -7.46 | 3.4 μM | 100 | 11 | Glu300, Lys162 | Ala470, Cys159, Leu441, Phe324, Phe474, Pro443, Thr471, Thr472, Tyr296, Val473-10 |
| Tgr/isop | -7.37 | 3.97 μM | 100 | 22 | Glu300, Lys162(2), Thr472 | Ala470, Cys159, Leu441, Phe324, Phe474, Pro443, Thr471, Tyr296, Val473-9 |
| Tgr/epi | -7.25 | 4.89 μM | 100 | 27 | Lys162(2), Thr442 | Cys159, Gly158, Glu300, Leu441, Phe280, Phe474, Pro443, Thr472, Tyr296, Val157, Val297, Val473-12 |
| Up/isop | -7.19 | 5.37 μM | 100 | 64 | Arg50 (2), Arg121, Gln201, Thr124 (2) | Arg121, Gly123, Glu232, Met93, Met231, Met233, Phe197, Phe272-8 |
| Pnp/epi | -7.18 | 5.46 μM | 100 | 40 | Ala118(2), His88 | Asn117, Asn245, Ala119, Gly120, Gly220, Glu203, His259, Met221, Pro200, Tyr90, Tyr202, Val219–12 |
| Up/epi | -7.16 | 5.68 μM | 100 | 33 | Arg50, Arg121(2), Thr124, Glu234, Gly46 | Gly92, Gly123, Glu232, His91, Met93, Met231, Phe197, Phe272, Ser125–9 |
| Tgr/pilo | -7.13 | 5.95 μM | 100 | 20 | Lys162, Thr442 | Ala470, Cys159, Glu300, Leu441, Phe474, Pro443, Thr471, Thr472, Tyr296-9 |
| Pnp/epiis | -7.11 | 6.19 μM | 100 | 75 | Ala118(2), Met221, Ser222 | Asn117, Asn245, Gly120, Gly220, His88, His259, Tyr90, Tyr202, Thr244, Val219-10 |
| Pnp/pilo | -7.08 | 6.47 μM | 100 | 41 | Ala118, Arg86, Met221 | Ala119, Asn245, Gly34, Gly120, Gly220, Glu203, His88, Ser222, Tyr90, Tyr202, Val219–11 |
| Mtap/isop | -6.91 | 8.55 μM | 100 | 8 | Ala88, Asn205, Met206 | Ile182, Val204, Ser12, Phe187, Asp232, Gly90, Asp230, Thr229, Cys89, Thr207, His55 |
| Pnp/isop | -6.83 | 9.84 μM | 100 | 8 | Ala118, Met221 | Asn117, Asn245, Ala119, Arg86, Gly34, Gly120, Gly220, Glu203, His88, Ser35, Ser222, Tyr90, Tyr202, Val219-14 |
| Up/pilo | -6.74 | 11.54 μM | 100 | 99 | Arg203 (2), Gln201, Met231 | Arg121, Gly126, Glu232, Glu234, Ile265, Met233, Phe197, Phe272, Ser125, Thr124-10 |
| Arg/pilo | -6.64 | 13.47 μM | 100 | 1 | Asn169, His171(2), Gly157 | Glu307, Thr276, Asp158, Asp262, Asp264, His156, Asp211, Glu216, Asn160, Asp213, Gly172-11 |
| Mtap/epiis | -6.63 | 13.72 μM | 100 | 1 | Asp230, Ser188 | Ala88, Asn205, ILe182, Val204, Phe187, Met206, Gly90, Thr229, Cys89, Asp232 |
| Mtap/epi | -6.54 | 15.97 μM | 100 | 33 | Ala88, His55, Met206, Ser12 | Thr229, Pro63, Phe187, Asp320, Cys89, Val204, Gly90, Thr207, Asn205 |
| 2cb1/epiis | -6.52 | 16.65 μM | 100 | 2 | Gln94, Gly144, Gly269, His270 | Cys100, Gly98, Gly143, Leu252, Leu267, Ser99, Trp101, Trp292, Val247 |
| Mtap/pilo | -6.51 | 16.97 μM | 100 | 84 | Ala88, Asn205, Met206, Val204 | Thr229, Cys89, Ile182, Phe187, Asp232, Gly90, Asp230 |
| Arg/epi | -6.48 | 17.71 μM | 100 | 54 | Ala166, Ser165 | Met173, Asn169, Gly172, His171, Asp158, Asp262, Asp264, Thr276, Asn160, Asp213, Ser167-11 |
| Arg/epiis | -6.44 | 19.07 μM | 100 | 16 | Asn169 (2) | Gly172, Ser167, His171, Thr276, Gly157, His156, Glu216, Asp 158, Asp213, Asn160, Asp211, Ser165, Ala166-13 |
| Hdac8/epi | -6.43 | 19.44 μM | 100 | 54 | - | Tyr99, Asp100, Phe151, Pro19, Tyr153, Lys20, Phe21, Pro102, Phe104, Tyr110, Ser18 |
| Arg/isop | -6.4 | 20.34 μM | 100 | 72 | Ala166, Asp158, Ser165, Ser167 | Asp213, Glu216, Asp211, His156, Gly157, His171, Met173, Asn160, Gly172, Asn169-10 |
| 2cb1/isop | -6.23 | 27.3 μM | 100 | 8 | Gln94, Gly269, Cys100, His270, Gly269 | Gly98, Gly143, Gly144, Gly268, His181, Leu252, Leu267, Trp292, Val247 |
| 2cb1/pilo | -6.18 | 29.35 μM | 100 | 10 | Gly144(2), Gln94 | Ala271, Cys100, Gly98, Gly143, Gly244, Gly269, Glu316, His270, Leu146, Trp101 |
| Up/mac | -6.15 | 31.19 μM | 100 | 97 | Arg50, Gly46, Thr124 | Arg121, Gly92, Gly123, Gln201, Glu232, Glu234, His91, Met93, Met233, Phe197-10 |
| Hdac8/epiis | -6.14 | 31.78 μM | 100 | 7 | His141, His292, | Asp184, His142, Gly338, Asp186, Phe216, Gly150, Asp100, Asp285, Typ140, Phe21, Tyr341, His188, Phe151, Asp290 |
| 2cb1/epi | -6.09 | 34.36 μM | 100 | 10 | Gly144(2), Trp101 | Ala271, Cys100, Gln94, Gly98, Gly143, Gly269, Glu316, His270, Leu146 |
| 2cb1/mac | -6.09 | 34.09 μM | 100 | 2 | Ala127, Phe175 | Asp93, Arg92, Gly161, Glu124, Glu165, Lys164, Lys177, Ser126, Ser162, Ser163, Phe103, Tyr173 |
| Arg/mac | -5.6 | 78.59 μM | 100 | 100 | Asp158, Gly157 | Ser165, Asn169, Asn160, Ser167, Gly172, Ala166, His156, Glu216, Asp211-9 |
| Mtap/mac | -5.54 | 87.42 μM | 100 | 100 | Ser188 | Thr229, Cys89, Gly90, Asp230, Asp232, Phe187, Ala88, Asn205, Val204, Met206, Ile182 |
| Hdac8/pilo | -5.54 | 87.15 μM | 100 | 2 | Tyr99 | Phe104, Pro102, Tyr153, Asp100, Ser18, Pro19, Lys20, Phe151 |
| Hdac8/isop | -5.41 | 108.27 μM | 100 | 14 | Asp186, Asp285, His188, Phe216 | His292, Phe215, Asp100, Gly150, Tyr341, Phe151, His142 |
| Hdac8/mac | -5.38 | 113.26 μM | 100 | 61 | - | Asp100, Pro102, Tyr153, Phe104, Tyr110, Lys20, Tyr99, Phe151, Ser18, Pro19 |
| Tgr/mac | -5.36 | 117.12 μM | 100 | 1 | Cys154, Thr153 | Ala256, Ala445, Asp433, Gly118, Gly258, Gly432, Ile431, Ile434, Leu441, Ser117, Thr442-11 |
| Pnp/mac | -5.36 | 118.65 μM | 100 | 13 | Asn245, Tyr90 | Asn117, Ala118, Ala119, Gly120, Gly220, His88, Met221, Ser222, Tyr194, Tyr202, Thr244, Val219, Val262-13 |
a Binding energy of the best conformation
b Inhibition constant of the best conformation
c Obtained using Ligplot+ software
Fig 7Molecular docking of the epiisipilosine alkaloid with the UP enzyme of S. mansoni.
a) 2D scheme showing the hydrogen bonds and hydrophobic interactions in the EPIIS-UP complex. b) 3D interactions by hydrogen bonds (Gln201, Met231 and Arg203) in EPIIS. c) 3D conformation of the active site of EPIIS binding in UP enzyme.
Fig 8Molecular docking showing the active site of the TGR enzyme with the alkaloids and their interactions by hydrogen bonds.
a) epiisopiloturine, b) epiisopilosine, c) isopilosine, d) pilosine, and e) macaubina.